ONCOLOGY
To support drug discovery projects in oncology, we perform high-content analysis either in cellular models of human tumors in 2D or 3D, or directly in tumor tissues and blood samples. Combining a panel of validated assays for immediate performance and more than 10-year experience in assay development, we assist pharmaceutical companies and academic researchers in the discovery of new cancer drug targets, the identification of new anticancer compounds, and the quantitative analysis of novel cancer biomarkers.
Fluofarma maintains a panel of human cancer cell lines to establish in vitro tumor models in 2D or 3D. Isolated from tissue-specific tumors and grown in vitro, cancer cell lines are particularly suited for anti-cancer drug screening.
(Please contact us if you want us to test your compounds in a specific model: several cell lines are available for each tumor type, and our panel is regularly augmented with new cell lines)
LYMPHATIC SYSTEM | Burkitt's lymphoma Diffuse large B cell lymphoma Follicular lymphoma Hodgkin's lymphoma Non-Hodgkin's B cell lymphoma |
IMMUNE SYSTEM | Acute T cell leukemia Acute lymphoblastic leukemia Monocyte leukemia Promyelocytic leukemia |
MAMMARY SYSTEM | Breast carcinoma |
DIGESTIVE SYSTEM CARCINOMAS |
Colorectal carcinoma Hepatoma Pancreas carcinoma |
UROGENITAL SYSTEM | Bladder carcinoma Cervical adenocarcinoma Prostate carcinoma |
BRAIN & ENDOCRINE SYSTEM TUMORS |
Glioblastoma Neuroblastoma Pheochromocytoma Pituitary adenoma |
SKIN AND SOFT TISSUES CANCERS |
Fibrosarcoma Melanoma |
LUNG CANCER | Alveolar basal epithelial lung Adenocarcinoma |
Fluofarma has applied its proprietary biosensor technology (DAPS) to a number of cell lines within this panel, thus allowing the reagent-less quantification of caspase, gamma-secretase and calpain activity by high-throughput flow cytometry.
>>> Learn more about our drug discovery services in oncology, or more generally, about our preclinical services.